0B68 McCue, Peter A. - Thomas Jefferson University - Thomas Jefferson University
pxm129

Peter A. McCue, MD

Contact Dr. McCue

132 S. 10th Street
Main Building, Suite 285
Philadelphia, PA 19107

(215) 955-5588

Most Recent Peer-reviewed Publications

  1. Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in T 111C rophoblastic Tumors
  2. VPAC1 targeted 64Cu-TP3805 positron emission tomography imaging of prostate cancer: Preliminary evaluation in man
  3. Structure-based screen identifies a potent small molecule inhibitor of Stat5a/b with therapeutic potential for prostate cancer and chronic myeloid leukemia
  4. Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
  5. The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a CXCL signaling module
  6. Sox10 - A marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: A systematic analysis of 5134 tumors
  7. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer
  8. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy
  9. A systematic immunohistochemical study of 3215 cases
  10. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
  11. GATA3: A multispecific but potentially useful marker in surgical pathology: A systematic analysis of 2500 epithelial and nonepithelial tumors
  12. Mapping of succinate dehydrogenase losses in 2258 epithelial neoplasms
  13. Predictors of positive surgical margins after radical prostatectomy at a single institution: Preoperative and pathologic factors, and the impact of surgeon variability and technique on incidence and location
  14. Targeting cell cycle and hormone receptor pathways in cancer
  15. Pharmacologic inhibition of Jak2-Stat5 signaling by Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate 084E cancer
  16. Sarcoidosis mimicking metastatic bone disease in head and neck cancer
  17. STAT5A/B gene locus undergoes amplification during human prostate cancer progression
  18. Molecular diagnosis of prostate cancer: Are we up to age?
  19. Aberrant BAF57 signaling facilitates prometastatic phenotypes
  20. Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures
0